Phase 2 N=18 A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
Primary: Best Overall Response Rate (ORR) — 0.0 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)
Nasopharyngeal Carcinoma
Primary: Rate of Completion of All Adjuvant Immunotherapy — 100 percentage of participants
Phase 2 N=100 Study of Cetuximab in Nasopharyngeal Carcinoma (NPC) With Chemoradiotherapy
Nasopharyngeal Carcinoma
Primary: 3 Month Loco-regional Control After Cetuximab With Concurrent Chemoradiotherapy — 100 participants with loco-regional control
Phase 2 N=26 Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
Stage II Lymphoepithelioma of the Nasopharynx · Stage II Squamous Cell Carcinoma of the Nasopharynx · Stage III Lymphoepithelioma of the Nasopharynx
Primary: Number of Participants With Progression-free Survival (PFS) at 2 Years After Chemo-radiotherapy — 18; 4 Participants
Phase 2 N=28 Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients
Effect of Drugs
Primary: Objective Response Rate (ORR) Before First PD — 60.7 Percentage of Participants
Phase 2 N=45 Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
Nasopharyngeal Nonkeratinizing Carcinoma · Recurrent Nasopharynx Carcinoma · Stage III Nasopharyngeal Carcinoma AJCC v7
Primary: Confirmed Response Rate (Complete Response or Partial Response) Based on RECIST Version 1.1 — 20.5 percentage of patients with a response
Phase 2 N=25 High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
Head and Neck Cancer
Primary: Survival Rate of Patients — 33 months
Phase 3 N=330 A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients
Nasopharyngeal Carcinoma
Primary: Overall Survival (OS) of Subjects With Advanced Nasopharyngeal Carcinoma. — 25; 24.9 Months — p=0.1942
Phase 2 N=46 Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage III Nasopharyngeal Undifferentiated Carcinoma AJCC v7
Primary: Percentage of Patients With a Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the…
Phase 2 N=34 Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
Oropharyngeal Squamous Cell Cancer
Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale
Phase 2 N=31 Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma
NK/T-cell Lymphoma of Nasal Cavity
Primary: Compete Response Rate — 31 participants
Phase 3 N=111 Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 · Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7 · Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
Primary: Two Year Event-free Survival (EFS) — 0.87 Estimated probability
Phase 2 N=69 Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: 2-year Progression-free Survival Rate — 47 proportion of participants
Phase 2 N=68 Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
Head and Neck Cancer · Oral Complications of Radiation Therapy · Radiation Toxicity
Primary: Protocol Compliance of Intensity-modulated Radiotherapy Treatment Delivered — 9 participants
Phase 2 N=30 A Phase 2 Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Lymphoma, Non-Hodgkin · Lymphoma · Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Primary: Overall ObjectiveResponse (ORR) Rate — 0; 7; 19; 4 participants
Phase 1 N=40 LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Hodgkin Disease · Non Hodgkin Lymphoma · Lymphoepithelioma
Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…
Phase 2 N=72 Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
Phase 2 N=33 Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer
Recurrent Lymphoepithelioma of the Nasopharynx · Recurrent Squamous Cell Carcinoma of the Nasopharynx · Stage IV Lymphoepithelioma of the Nasopharynx
Primary: Clinical Benefit Rate — 54.5 percentage of participants
Phase 2 N=39 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Head and Neck Cancer
Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants
Phase 2 N=25 Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Phase 2 N=36 Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
Nasopharyngeal Neoplasms
Primary: Percentage of Participants Who Achieved a Complete or Partial Response According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) Based on an Independent…
Phase 2 N=62 Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Recurrent Head and Neck Squamous Cell Carcinoma
Primary: Number of Participants With Progression-Free Survival (PFS) — 27 Participants
Phase 2 N=30 CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Phase 2 N=67 INRT-AIR: A Prospective Phase II Study of Involved Nodal Radiation Therapy
Head and Neck Squamous Cell Carcinoma
Primary: Risk of Solitary Elective Volume Recurrence Following Elective Volume Reduction Using INRT — 11; 9; 3; 6 percentage of participants
Phase 2 N=17 Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck
Head and Neck Squamous Cell Carcinoma
Primary: Locoregional Control — 17 participants
Phase 2 N=72 Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Phase 2 N=194 Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Burkitt Lymphoma · Diffuse Large B-cell Lymphoma, c-MYC Positive · Plasmablastic Lymphoma
Primary: Percentage of Participants With Kaplan-Meier Curve Progression Free Survival (PFS) Constructed With an 95% Confidence Interval — 100; 82.1; 71.0 percentage of participants
Phase 2 N=87 Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 68.0; 50.0; 16.0; 14.3 Percentage of participants
Phase 2 N=100 Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
Non-Small Cell Lung Cancer · Epigenetic Therapy
Primary: Objective Response — 4; 1; 5; 3 Participants
Phase 2 N=58 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
EBV-induced Lymphomas · EBV-associated Malignancies · Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Primary: Objective Response Rate (ORR) — 63.6; 50.0; 0; 43.5 Percentage of participants